company background image
QURE

uniQure NasdaqGS:QURE Stock Report

Last Price

US$26.90

Market Cap

US$1.3b

7D

21.3%

1Y

-6.7%

Updated

27 Nov, 2022

Data

Company Financials +
QURE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

QURE Stock Overview

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases.

uniQure N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for uniQure
Historical stock prices
Current Share PriceUS$26.90
52 Week HighUS$30.41
52 Week LowUS$12.52
Beta0.95
1 Month Change48.46%
3 Month Change35.59%
1 Year Change-6.66%
3 Year Change-51.67%
5 Year Change72.88%
Change since IPO84.12%

Recent News & Updates

uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion

Sep 21

uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch

Aug 30

Recent updates

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

Aug 14
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

Jun 08
These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

May 04
uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings

Mar 04
We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings

The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

Feb 27
The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically

Is uniQure (NASDAQ:QURE) A Risky Investment?

Feb 23
Is uniQure (NASDAQ:QURE) A Risky Investment?

These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

Oct 24
These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely

Is uniQure N.V. (NASDAQ:QURE) Trading At A 48% Discount?

Sep 19
Is uniQure N.V. (NASDAQ:QURE) Trading At A 48% Discount?

Shareholders May Be A Little Conservative With uniQure N.V.'s (NASDAQ:QURE) CEO Compensation For Now

Jun 10
Shareholders May Be A Little Conservative With uniQure N.V.'s (NASDAQ:QURE) CEO Compensation For Now

Need To Know: Analysts Are Much More Bullish On uniQure N.V. (NASDAQ:QURE)

May 21
Need To Know: Analysts Are Much More Bullish On uniQure N.V. (NASDAQ:QURE)

Is uniQure (NASDAQ:QURE) A Risky Investment?

May 09
Is uniQure (NASDAQ:QURE) A Risky Investment?

uniQure N.V.'s (NASDAQ:QURE) Has Found A Path To Profitability

Apr 12
uniQure N.V.'s (NASDAQ:QURE) Has Found A Path To Profitability

uniQure N.V.'s (NASDAQ:QURE) Intrinsic Value Is Potentially 83% Above Its Share Price

Mar 22
uniQure N.V.'s (NASDAQ:QURE) Intrinsic Value Is Potentially 83% Above Its Share Price

If You Had Bought uniQure (NASDAQ:QURE) Shares Five Years Ago You'd Have Earned 162% Returns

Mar 01
If You Had Bought uniQure (NASDAQ:QURE) Shares Five Years Ago You'd Have Earned 162% Returns

Have Insiders Sold uniQure N.V. (NASDAQ:QURE) Shares Recently?

Feb 01
Have Insiders Sold uniQure N.V. (NASDAQ:QURE) Shares Recently?

Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

Dec 29
Is uniQure (NASDAQ:QURE) Using Debt Sensibly?

Is uniQure N.V. (NASDAQ:QURE) Trading At A 30% Discount?

Dec 03
Is uniQure N.V. (NASDAQ:QURE) Trading At A 30% Discount?

Shareholder Returns

QUREUS BiotechsUS Market
7D21.3%0.4%1.3%
1Y-6.7%-14.4%-18.5%

Return vs Industry: QURE exceeded the US Biotechs industry which returned -14.4% over the past year.

Return vs Market: QURE exceeded the US Market which returned -18.5% over the past year.

Price Volatility

Is QURE's price volatile compared to industry and market?
QURE volatility
QURE Average Weekly Movement9.5%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: QURE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: QURE's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998463Matt Kapustahttps://www.uniqure.com

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson’s disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer’s disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

uniQure N.V. Fundamentals Summary

How do uniQure's earnings and revenue compare to its market cap?
QURE fundamental statistics
Market CapUS$1.26b
Earnings (TTM)-US$125.39m
Revenue (TTM)US$61.43m

20.5x

P/S Ratio

-10.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
QURE income statement (TTM)
RevenueUS$61.43m
Cost of RevenueUS$171.32m
Gross Profit-US$109.89m
Other ExpensesUS$15.50m
Earnings-US$125.39m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.68
Gross Margin-178.88%
Net Profit Margin-204.12%
Debt/Equity Ratio24.3%

How did QURE perform over the long term?

See historical performance and comparison